UroMems has raised US$60m from Ajax Health Fund I to support pivotal trials of its UroActive implant in the US and France ahead of regulatory submissions.
The round is the company’s largest fundraising to date and comes less than a year after its US$47m Series C financing in June 2024.
Co-founder Hamid Lamraoui said: Lamraoui said: “Ajax Health Fund I’s support strengthens our position as we near FDA PMA submission and commercialisation.
“We believe UroActive can transform SUI treatment and bring a better option to patients and physicians.”
Founded in 2011 by Lamraoui and Georges El Fassi, UroMems develops implantable mechatronics technology for stress urinary incontinence, known as SUI.
It says this condition affects an estimated 40m people in the US and 90m in Europe.
Its lead product, UroActive, is an automated artificial urinary sphincter powered by a MyoElectroMechanical System (MEMS).
The implant is placed around the urethral duct and automatically adjusts according to patient activity, removing the need for manual operation.
The device is designed for both men and women suffering from sphincter insufficiency.”
The company’s technology platform is protected by more than 200 granted patents. UroMems is competing with traditional artificial urinary sphincter manufacturers including Boston Scientific and Zephyr Surgical Implants, whose devices still rely on manual activation.
The latest financing will support the ongoing SOPHIA2 clinical trial taking place across 21 investigational centres in the US and France.
Data from the study will be used for regulatory submissions in both markets.
David Beylik, partner at Ajax Health, said: “Combining our industry experience and capital with the UroMems team, we believe that the UroActive smart implant has the potential to become the l standard of care for SUI treatment.”
Researchers train immune system to tackle drug-resistant infections
